Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase PKCi]
Substrate: MARCKS

Description: Myristoylated alanine-rich C-kinase substrate (MARCKS) (Protein kinaseC substrate, 80 kDa protein, light chain) (PKCSL) (80K-L protein).

Synonyms: MACS, PRKCSL

Ensembl ID: ENSG00000155130

UniprotKB/SwissProt: MARCS_HUMAN (P29966)

Function: MARCKS is the most prominent cellular substrate for protein kinase C. This protein binds calmodulin, actin, and synapsin. MARCKS is a filamentous (F) actin cross-linking protein.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Cytoplasm, cytoskeleton (Probable). Membrane; Lipid-anchor (By similarity).
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of MARCKS

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1MARCKSMARCS_HUMANS26EAAVA S SPSKA 35.86% Swiss-Prot 55.0 View   
2MARCKSMARCS_HUMANS26EAAVA S SPSKA 35.86% Phospho.ELM 7.0View   
3MARCKSMARCS_HUMANS27AAVAS S PSKAN 24.37% Phospho.ELM 7.0View   
4MARCKSMARCS_HUMANS27AAVAS S PSKAN 24.37%PKCa HPRD:07519(in vitro;in vivo)  ViewAnalyzing
5MARCKSMARCS_HUMANS27AAVAS S PSKAN 24.37% Swiss-Prot 55.0 View   
6MARCKSMARCS_HUMANS29VASSP S KANGQ 46.47% Swiss-Prot 55.0 View   
7MARCKSMARCS_HUMANS29VASSP S KANGQ 46.47% Phospho.ELM 7.0View   
8MARCKSMARCS_HUMANS46VNGDA S PAAAE 21.58% Swiss-Prot 55.0 View   
9MARCKSMARCS_HUMANS46VNGDA S PAAAE 21.58% Phospho.ELM 7.0View   
10MARCKSMARCS_HUMANS46VNGDA S PAAAE 21.58%PKCa HPRD:07519(in vitro;in vivo)  ViewAnalyzing
11MARCKSMARCS_HUMANS77PAAAG S GAASP 22.11% Swiss-Prot 55.0 View   
12MARCKSMARCS_HUMANS81GSGAA S PSAAE 20.89%PKCa HPRD:07519(in vitro;in vivo)  ViewAnalyzing
13MARCKSMARCS_HUMANS81GSGAA S PSAAE 20.89% Swiss-Prot 55.0 View   
14MARCKSMARCS_HUMANS101PEAGA S PVEKE 28.67%PKCa HPRD:07519(in vitro;in vivo)  ViewAnalyzing
15MARCKSMARCS_HUMANS101PEAGA S PVEKE 28.67% Swiss-Prot 55.0 View   
16MARCKSMARCS_HUMANS101PEAGA S PVEKE 28.67% Phospho.ELM 7.0View   
17MARCKSMARCS_HUMANS118AAEPG S PTAAE 29.77%PKCa HPRD:07519(in vitro;in vivo)  ViewAnalyzing
18MARCKSMARCS_HUMANS118AAEPG S PTAAE 29.77%MAPK_group Swiss-Prot 55.0 (Similarity) ViewAnalyzing
19MARCKSMARCS_HUMANS128EGEAA S AASST 31.26% Phospho.ELM 7.0View   
20MARCKSMARCS_HUMANS135ASSTS S PKAED 30.43% Swiss-Prot 55.0 (Similarity)View   
21MARCKSMARCS_HUMANS135ASSTS S PKAED 30.43% Phospho.ELM 7.0View   
22MARCKSMARCS_HUMANS135ASSTS S PKAED 30.43% HPRD:07519(in vitro)View   
23MARCKSMARCS_HUMANT143AEDGA T PSPSN 29.81% Phospho.ELM 7.0View   
24MARCKSMARCS_HUMANT143AEDGA T PSPSN 29.81% Swiss-Prot 55.0 View   
25MARCKSMARCS_HUMANS145DGATP S PSNET 36.28% Phospho.ELM 7.0View   
26MARCKSMARCS_HUMANS145DGATP S PSNET 36.28% Swiss-Prot 55.0 View   
27MARCKSMARCS_HUMANS147ATPSP S NETPK 52.19% Swiss-Prot 55.0 (Similarity)View   
28MARCKSMARCS_HUMANT150SPSNE T PKKKK 44.66% Phospho.ELM 7.0View   
29MARCKSMARCS_HUMANT150SPSNE T PKKKK 44.66% HPRD:07519(in vitro)View   
30MARCKSMARCS_HUMANT150SPSNE T PKKKK 44.66% Swiss-Prot 55.0 View   
31MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKCb HPRD:07519(in vitro)  ViewAnalyzing
32MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKC_group Phospho.ELM 7.0 ViewAnalyzing
33MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKN1 HPRD:07519(in vitro)  ViewAnalyzing
34MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKCa HPRD:07519(in vitro)  ViewAnalyzing
35MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKC_group Swiss-Prot 55.0  ViewAnalyzing
36MARCKSMARCS_HUMANS159KKKRF S FKKSF 39.94%PKCa(PKC alpha) Phospho.ELM 7.0 ViewAnalyzing
37MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKCa HPRD:07519(in vitro)  ViewAnalyzing
38MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKC_group Swiss-Prot 55.0  ViewAnalyzing
39MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKCb HPRD:07519(in vitro)  ViewAnalyzing
40MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKN1 HPRD:07519(in vitro)  ViewAnalyzing
41MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKC_group Phospho.ELM 7.0 ViewAnalyzing
42MARCKSMARCS_HUMANS163FSFKK S FKLSG 28.36%PKCa(PKC alpha) Phospho.ELM 7.0 ViewAnalyzing
43MARCKSMARCS_HUMANS167KSFKL S GFSFK 38.08%PKCa HPRD:07519(in vitro)  ViewAnalyzing
44MARCKSMARCS_HUMANS167KSFKL S GFSFK 38.08%PKC_group Swiss-Prot 55.0  ViewAnalyzing
45MARCKSMARCS_HUMANS167KSFKL S GFSFK 38.08%PKC_group Phospho.ELM 7.0 ViewAnalyzing
46MARCKSMARCS_HUMANS170KLSGF S FKKNK 39.42%PKC_group Swiss-Prot 55.0  ViewAnalyzing
47MARCKSMARCS_HUMANS170KLSGF S FKKNK 39.42%PKC_group Phospho.ELM 7.0 ViewAnalyzing
48MARCKSMARCS_HUMANS170KLSGF S FKKNK 39.42%PKCa HPRD:07519(in vitro)  ViewAnalyzing
49MARCKSMARCS_HUMANS170KLSGF S FKKNK 39.42%PKN1 HPRD:07519(in vitro)  ViewAnalyzing
50MARCKSMARCS_HUMANS170KLSGF S FKKNK 39.42%PKCb HPRD:07519(in vitro)  ViewAnalyzing
51MARCKSMARCS_HUMANS262AAEEP S KVEEK 53.25% HPRD:07519(in vitro)View   
52MARCKSMARCS_HUMANS262AAEEP S KVEEK 53.25% Swiss-Prot 55.0 (Similarity)View